Pfizer may present new growth hormone in 2022
The EMA has accepted Pfizer's and Opko's application to get a new growth hormone approved, which may compete with Novo Nordisk's and Ascendis' growth hormons.
BY ELIZABETH MØNSTED JOHANSEN, TRANSLATED BY NIELSINE NIELSEN
The European Medicines Agency (EMA) has approved a Pfizer and Opko application concerning their joint growth hormone somatrogon.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Astrazeneca's CEO and colleagues grilled at EU Hearing
For subscribers
Experts: Mandatory release of patents highly unlikely
For subscribers
.jpg&w=384&q=75)
